Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zura BioFRA:94E -1.29%25 Forward Dividend Yield % is 0.00% as of Jul. 26, 2026. GuruFocus rates FRA:94E with a GF Score™ of 25/100. Among 149 Biotechnology companies, Zura Bio ranks worse than 671140.27% on this metric.
As of today (2026-07-26), the Forward Annual Dividend Yield of Zura Bio is 0.00%.
As of today (2026-07-26), the Trailing Annual Dividend Yield of Zura Bio is 0.00%.
FRA:94E's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.35 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Zura Bio (FRA:94E) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
FRA:94E vs KYTX, ARVN, CBIO: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Zura Bio's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zura Bio Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zura Bio's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Zura Bio's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Zura Bio (FRA:94E) has a Forward Dividend Yield % of 0.00% as of Jul. 26, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Zura Bio and its competitors. According to the industry distribution chart, Zura Bio ranks #999999 out of 149 companies in the Biotechnology industry.
Is Zura Bio's Forward Dividend Yield % too high?
Zura Bio's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Zura Bio ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zura Bio has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Zura Bio's Forward Dividend Yield % compare to KYTX and ARVN?
According to the Biotechnology industry distribution chart, Zura Bio ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Zura Bio in the lower half of its industry. The industry median Forward Dividend Yield % is 1.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.35, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Zura Bio and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zura Bio's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zura Bio stock overvalued right now?
Zura Bio (FRA:94E) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Zura Bio's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Zura Bio (FRA:94E), the current Forward Dividend Yield % is 0.00% as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
25GF Score
Get the complete analysis for FRA:94E
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:94E has been successfully added to your 
